摘要
2004年至今,国家医保部门开展了多次药品目录调整及准入谈判,在此过程中积累的经验有助于近期实现目录的动态调整。创新药准入是动态调整工作的重要组成部分,本文通过梳理既往的目录调整政策、组织机构、流程方法,结合部分国家和地区成熟经验,提出完善创新药医保准入的若干思路,以期为进一步提升创新药的评审和遴选效率、促进准入流程及方法更加科学透明提供参考。
Since 2004, several rounds of medical insurance drug list adjustments and access negotiations had been conducted, which set the foundation for dynamic adjustment. The reimbursement access of innovative drugs will be a critical part in dynamic adjustment. This article summarized relevant policy, organizational structure, process and methodology as well as international experience, to discuss and shape a more efficient, transparent and scientific approach for dynamic adjustment.
作者
范长生
王丽莉
吴久鸿
Fan Changsheng;Wang Lili;Wu Jiuhong(Beijing Medical and Health Economic Research Association,Beijing,100069;Center for Health Technology Assessment and Medical Policy,Renmin University of China,Beijing,100872;Characteristic Medical Center of Strategic Support Force of PLA,Beijing,100102)
出处
《中国医疗保险》
2020年第5期63-67,共5页
China Health Insurance
关键词
医保目录
动态调整
创新药
准入
medical insurance drug list
dynamic adjustment
innovative drug
reimbursement access
